Sayari Dewan, Himanshu Sonker, Kajal Chaudhary and Ritika Gautam Singh
{"title":"金(i)-NHC配合物抗癌剂的合理设计:诱导肺腺癌的坏死和旁凋亡。","authors":"Sayari Dewan, Himanshu Sonker, Kajal Chaudhary and Ritika Gautam Singh","doi":"10.1039/D5MD00290G","DOIUrl":null,"url":null,"abstract":"<p >Gold(<small>I</small>)-NHC complexes bearing sterically demanding ligands remain largely underexplored as anticancer agents. In this study, we rationally designed and synthesized a series of gold(<small>I</small>)-NHC complexes derived from cytotoxic 1,10-phenanthroline-based NHC ligands. Comprehensive structural characterization was performed using <small><sup>1</sup></small>H and <small><sup>13</sup></small>C NMR spectroscopy, ESI-MS, IR spectroscopy, and single-crystal X-ray diffraction. Among the synthesized complexes <strong>AuL1–AuL7</strong>, <strong>AuL4</strong> emerged as the most active compound, exhibited potent anticancer activity, triggering mitochondrial membrane depolarization and inducing necroptosis and paraptosis in human lung adenocarcinoma (A549) cells—a mechanism distinct from conventional apoptosis-inducing gold complexes. Notably, <strong>AuL4</strong> effectively suppressed both metastasis and clonal expansion of malignant cells, reinforcing the therapeutic potential of gold-based chemotherapeutics. These findings establish <strong>AuL4</strong> and its analogues as promising candidates for the development of next-generation gold(<small>I</small>)-NHC anticancer agents, particularly for treating apoptosis-resistant lung cancers.</p>","PeriodicalId":88,"journal":{"name":"MedChemComm","volume":" 9","pages":" 4208-4219"},"PeriodicalIF":3.5970,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Rational design of gold(i)-NHC complexes as anticancer agents: induction of necroptosis and paraptosis in lung adenocarcinoma†\",\"authors\":\"Sayari Dewan, Himanshu Sonker, Kajal Chaudhary and Ritika Gautam Singh\",\"doi\":\"10.1039/D5MD00290G\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p >Gold(<small>I</small>)-NHC complexes bearing sterically demanding ligands remain largely underexplored as anticancer agents. In this study, we rationally designed and synthesized a series of gold(<small>I</small>)-NHC complexes derived from cytotoxic 1,10-phenanthroline-based NHC ligands. Comprehensive structural characterization was performed using <small><sup>1</sup></small>H and <small><sup>13</sup></small>C NMR spectroscopy, ESI-MS, IR spectroscopy, and single-crystal X-ray diffraction. Among the synthesized complexes <strong>AuL1–AuL7</strong>, <strong>AuL4</strong> emerged as the most active compound, exhibited potent anticancer activity, triggering mitochondrial membrane depolarization and inducing necroptosis and paraptosis in human lung adenocarcinoma (A549) cells—a mechanism distinct from conventional apoptosis-inducing gold complexes. Notably, <strong>AuL4</strong> effectively suppressed both metastasis and clonal expansion of malignant cells, reinforcing the therapeutic potential of gold-based chemotherapeutics. These findings establish <strong>AuL4</strong> and its analogues as promising candidates for the development of next-generation gold(<small>I</small>)-NHC anticancer agents, particularly for treating apoptosis-resistant lung cancers.</p>\",\"PeriodicalId\":88,\"journal\":{\"name\":\"MedChemComm\",\"volume\":\" 9\",\"pages\":\" 4208-4219\"},\"PeriodicalIF\":3.5970,\"publicationDate\":\"2025-06-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"MedChemComm\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://pubs.rsc.org/en/content/articlelanding/2025/md/d5md00290g\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"MedChemComm","FirstCategoryId":"1085","ListUrlMain":"https://pubs.rsc.org/en/content/articlelanding/2025/md/d5md00290g","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
Rational design of gold(i)-NHC complexes as anticancer agents: induction of necroptosis and paraptosis in lung adenocarcinoma†
Gold(I)-NHC complexes bearing sterically demanding ligands remain largely underexplored as anticancer agents. In this study, we rationally designed and synthesized a series of gold(I)-NHC complexes derived from cytotoxic 1,10-phenanthroline-based NHC ligands. Comprehensive structural characterization was performed using 1H and 13C NMR spectroscopy, ESI-MS, IR spectroscopy, and single-crystal X-ray diffraction. Among the synthesized complexes AuL1–AuL7, AuL4 emerged as the most active compound, exhibited potent anticancer activity, triggering mitochondrial membrane depolarization and inducing necroptosis and paraptosis in human lung adenocarcinoma (A549) cells—a mechanism distinct from conventional apoptosis-inducing gold complexes. Notably, AuL4 effectively suppressed both metastasis and clonal expansion of malignant cells, reinforcing the therapeutic potential of gold-based chemotherapeutics. These findings establish AuL4 and its analogues as promising candidates for the development of next-generation gold(I)-NHC anticancer agents, particularly for treating apoptosis-resistant lung cancers.
期刊介绍:
Research and review articles in medicinal chemistry and related drug discovery science; the official journal of the European Federation for Medicinal Chemistry.
In 2020, MedChemComm will change its name to RSC Medicinal Chemistry. Issue 12, 2019 will be the last issue as MedChemComm.